FI81006C - Foerfarande foer framstaellning av ett terapeutiskt aktivt komplex som bildas av platina, 1,2-diaminocyklohexan och polymerisk l-glutaminsyra. - Google Patents
Foerfarande foer framstaellning av ett terapeutiskt aktivt komplex som bildas av platina, 1,2-diaminocyklohexan och polymerisk l-glutaminsyra. Download PDFInfo
- Publication number
- FI81006C FI81006C FI834129A FI834129A FI81006C FI 81006 C FI81006 C FI 81006C FI 834129 A FI834129 A FI 834129A FI 834129 A FI834129 A FI 834129A FI 81006 C FI81006 C FI 81006C
- Authority
- FI
- Finland
- Prior art keywords
- platinum
- cis
- water
- complex
- glutamic acid
- Prior art date
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 62
- 229910052697 platinum Inorganic materials 0.000 claims description 24
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 claims description 21
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 18
- 125000000129 anionic group Chemical group 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 229960002989 glutamic acid Drugs 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 125000000524 functional group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 description 15
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 102100028735 Dachshund homolog 1 Human genes 0.000 description 11
- 101000915055 Homo sapiens Dachshund homolog 1 Proteins 0.000 description 11
- 229960004316 cisplatin Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 206010044708 Trypanosomal infections Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- GPNDARIEYHPYAY-UHFFFAOYSA-N palladium(ii) nitrate Chemical compound [Pd+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O GPNDARIEYHPYAY-UHFFFAOYSA-N 0.000 description 2
- 150000003057 platinum Chemical class 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 1
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- -1 H * NH 4+ Chemical class 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 241000096130 Toxopus brucei Species 0.000 description 1
- 241000223107 Trypanosoma congolense Species 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001099 anti-trypanosomal effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0013—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44044982A | 1982-11-10 | 1982-11-10 | |
| US44044982 | 1982-11-10 | ||
| US54087183 | 1983-10-14 | ||
| US06/540,871 US4584392A (en) | 1982-11-10 | 1983-10-14 | Platinum and palladium complexes |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI834129A0 FI834129A0 (fi) | 1983-11-10 |
| FI834129L FI834129L (fi) | 1984-05-11 |
| FI81006B FI81006B (fi) | 1990-05-31 |
| FI81006C true FI81006C (fi) | 1990-09-10 |
Family
ID=27032420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI834129A FI81006C (fi) | 1982-11-10 | 1983-11-10 | Foerfarande foer framstaellning av ett terapeutiskt aktivt komplex som bildas av platina, 1,2-diaminocyklohexan och polymerisk l-glutaminsyra. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4584392A (enExample) |
| EP (1) | EP0111388B1 (enExample) |
| AU (1) | AU566785B2 (enExample) |
| CA (1) | CA1227133A (enExample) |
| DE (1) | DE3370485D1 (enExample) |
| ES (1) | ES527111A0 (enExample) |
| FI (1) | FI81006C (enExample) |
| GR (1) | GR79429B (enExample) |
| IE (1) | IE56211B1 (enExample) |
| NO (1) | NO163693C (enExample) |
| PT (1) | PT77635B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4673754A (en) * | 1983-10-14 | 1987-06-16 | Inco Alloys International, Inc. | Platinum and palladium complexes |
| GB8328218D0 (en) * | 1983-10-21 | 1983-11-23 | Johnson Matthey Plc | Oral compositions |
| ES8801168A1 (es) * | 1984-11-02 | 1987-02-16 | Johnson Matthey Plc | Procedimiento para la obtencion de un compuesto de platino para utilizar en quimioterapia del cancer. |
| CS253069B1 (en) * | 1984-11-09 | 1987-10-15 | Jaroslav Drobnik | Macromolecular anticarcinogenetic remedy containing platinum and method of its production |
| IL73972A0 (en) * | 1984-12-31 | 1985-03-31 | Yeda Res & Dev | Agents based on platinum compounds |
| AU7481487A (en) * | 1986-05-21 | 1987-12-22 | Kuraray Co., Ltd. | Novel complexes, process for their preparation, and medicinal use of them |
| US5011959A (en) * | 1986-11-17 | 1991-04-30 | The Board Of Regents, The University Of Texas System | 1,2-diaminocyclohexane-platinum complexes with antitumor activity |
| US4882447A (en) * | 1987-02-20 | 1989-11-21 | Tanabe Seiyaku Co., Ltd. | Novel organic platinum complex and process for the preparation thereof |
| US4793986A (en) * | 1987-02-25 | 1988-12-27 | Johnson Matthey, Inc. | Macromolecular platinum antitumor compounds |
| IL85595A0 (en) * | 1987-03-06 | 1988-08-31 | Tanabe Seiyaku Co | Organic platinum complex and its preparation |
| CA1327354C (en) * | 1987-03-19 | 1994-03-01 | David Cullis-Hill | Anti-inflamatory compounds and compositions |
| EP0307827A3 (en) * | 1987-09-15 | 1989-12-27 | Kuraray Co., Ltd. | Novel macromolecular complexes, process for producing same and medicinal use of such complexes |
| US4931553A (en) * | 1988-05-11 | 1990-06-05 | Gill Devinder S | Platinum-polymer complexes and their use as antitumor agents |
| US5393909A (en) * | 1988-11-22 | 1995-02-28 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
| US5352771A (en) * | 1992-08-31 | 1994-10-04 | Iowa State University Research Foundation Inc. | Hydrolysis of peptide bonds using Pt (II) and Pd (II) complexes |
| US20070148721A1 (en) * | 2005-12-28 | 2007-06-28 | Agilent Technologies, Inc. | Compositions, methods, systems, and kits for affinity purification |
| JP6878619B2 (ja) * | 2018-02-06 | 2021-05-26 | ワッカー ケミー アクチエンゲゼルシャフトＷａｃｋｅｒ Ｃｈｅｍｉｅ ＡＧ | アミノプロピルアルコキシシランの製造方法 |
| CN113995714B (zh) * | 2021-10-28 | 2023-04-28 | 杭州师范大学 | 一种顺铂交联的蛋白水凝胶及制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH588505A5 (enExample) * | 1972-06-08 | 1977-06-15 | Research Corp | |
| GB1531211A (en) * | 1975-10-27 | 1978-11-08 | Rustenburg Platinum Mines Ltd | Compounds and compositions containing platinum |
| GB1541436A (en) * | 1976-02-02 | 1979-02-28 | Searle & Co | Immunological materials |
| US4356166A (en) * | 1978-12-08 | 1982-10-26 | University Of Utah | Time-release chemical delivery system |
| US4376782A (en) * | 1980-05-21 | 1983-03-15 | Research Corporation | Complexes of square planar platinum II compounds and N-methyl glucamine |
| JPS5851959B2 (ja) * | 1980-06-11 | 1983-11-19 | 呉羽化学工業株式会社 | プラチナ化合物とその医薬組成物 |
-
1983
- 1983-10-14 US US06/540,871 patent/US4584392A/en not_active Expired - Lifetime
- 1983-11-04 EP EP83306725A patent/EP0111388B1/en not_active Expired
- 1983-11-04 DE DE8383306725T patent/DE3370485D1/de not_active Expired
- 1983-11-08 CA CA000440644A patent/CA1227133A/en not_active Expired
- 1983-11-08 ES ES527111A patent/ES527111A0/es active Granted
- 1983-11-09 NO NO834089A patent/NO163693C/no unknown
- 1983-11-09 GR GR72935A patent/GR79429B/el unknown
- 1983-11-09 IE IE2614/83A patent/IE56211B1/en not_active IP Right Cessation
- 1983-11-09 PT PT77635A patent/PT77635B/pt not_active IP Right Cessation
- 1983-11-09 AU AU21109/83A patent/AU566785B2/en not_active Ceased
- 1983-11-10 FI FI834129A patent/FI81006C/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO834089L (no) | 1984-05-11 |
| NO163693C (no) | 1990-07-04 |
| IE832614L (en) | 1984-05-10 |
| EP0111388A2 (en) | 1984-06-20 |
| FI81006B (fi) | 1990-05-31 |
| IE56211B1 (en) | 1991-05-22 |
| AU566785B2 (en) | 1987-10-29 |
| FI834129A0 (fi) | 1983-11-10 |
| EP0111388A3 (en) | 1984-09-05 |
| FI834129L (fi) | 1984-05-11 |
| PT77635B (en) | 1986-03-19 |
| PT77635A (en) | 1983-12-01 |
| DE3370485D1 (en) | 1987-04-30 |
| NO163693B (no) | 1990-03-26 |
| CA1227133A (en) | 1987-09-22 |
| AU2110983A (en) | 1984-05-17 |
| US4584392A (en) | 1986-04-22 |
| GR79429B (enExample) | 1984-10-22 |
| EP0111388B1 (en) | 1987-03-25 |
| ES8504631A1 (es) | 1985-05-01 |
| ES527111A0 (es) | 1985-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI81006C (fi) | Foerfarande foer framstaellning av ett terapeutiskt aktivt komplex som bildas av platina, 1,2-diaminocyklohexan och polymerisk l-glutaminsyra. | |
| DeConti et al. | Clinical and pharmacological studies with cis-diamminedichloroplatinum (II) | |
| Mann et al. | Further studies of metal-metal bonded oligomers of rhodium (I) isocyanide complexes. Crystal structure analysis of octakis (phenyl isocyanide) dirhodium bis (tetraphenylborate) | |
| Ahmad et al. | Perspectives in bioinorganic chemistry of some metal based therapeutic agents | |
| US20040265237A1 (en) | Inclusion compound comprising cucurbituril derivatives as host molecule and pharmaceutical composition comprising the same | |
| van der Veer et al. | Reaction products from platinum (IV) amine compounds and 5'-GMP are mainly bis (5'-GMP) platinum (II) amine adducts | |
| US4452812A (en) | Organic complex of platinum, its preparation and its use for treating malignant tumors | |
| Schmidbaur et al. | Beryllium salicylate dihydrate | |
| KR910009823B1 (ko) | 백금착물(白金錯物) | |
| US20070207993A1 (en) | Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases | |
| US4673754A (en) | Platinum and palladium complexes | |
| Zhang et al. | Hexadentate β-Dicarbonyl (bis-catecholamine) Ligands for Efficient Uranyl Cation Decorporation: Thermodynamic and Antioxidant Activity Studies | |
| Reger et al. | Structural Comparisons of Silver (I) Complexes of Third-Generation Ligands Built from Tridentate (o-C6H4 [CH2OCH2C (pz) 3] 2) versus Bidentate Poly (1-pyrazolyl) methane Units (o-C6H4 [CH2OCH2CH (pz) 2] 2)(pz= Pyrazolyl Ring) | |
| US7632827B2 (en) | Anti-cancer phosphine containing [AuIIIm(CNC)mL]n+ complexes and derivatives thereof and methods for treating cancer using such compositions | |
| DE60105028T2 (de) | Ruthenium (ii) verbindungen in der krebsbehandlung | |
| US8519146B2 (en) | Metal complexes of N-heterocyclic carbenes as antibiotics | |
| Tsang et al. | Synthesis and crystal structure of silver and argentate complexes of mixed halocarborane anions,(C5H5N) 2Ag (1‐H CB11Br5I6)(C5H5N) and [{(CH3CN) 4Ag3}{Ag (CB11I5Br6) 2}] n | |
| CA1036618A (en) | Process for the manufacture of tris (2-hydroxyethyl) ammonium-ortho-cresosyacetate | |
| Sharma et al. | Structural varieties in Copper (II) aryl-carboxylates/-sulphonates with N-donor ligands | |
| EP0214862B1 (en) | Anti-tumour platinum complexes, their preparation and their use | |
| Chernova et al. | Molecular tectonics: from a binuclear metallamacrocycle to a 1D isostructural coordination network based on tetracyanomethyl [1.1. 1.1] metacyclophane and a silver cation | |
| RU2033998C1 (ru) | Комплексное соединение цис-диаминоплатины (ii) с сополимером na-соли малеиновой кислоты и фурана, обладающее иммуностимулирующей и противоопухолевой активностью, с широким интервалом терапевтических доз при низкой нефротоксичности | |
| EP0186363B1 (en) | Platinum complexes | |
| RU2034856C1 (ru) | Комплексное соединение цис-диамминоплатины (п) с сополимером na-соли малеиновой кислоты и 1,4-диизопропоксибутена-2, обладающее противоопухолевой активностью с широким интервалом терапевтических доз при полном отсутствии нефротоксичности и иммунодепрессантного действия | |
| RU2699809C9 (ru) | Катионно - анионные комплексы палладия |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: INCO RESEARCH & DEVELOPMENT CENTER, INC. |